

UNIVERSITY OF CALGARY

Development Of An Integrated Technology For The Removal Of Emerging Substances of **Concern From Municipal Wastewaters**

Muhammad Faizan Khan,[#] Gopal Achari,[†] Joo Hwa Tay[‡]

Department of Civil Engineering, University of Calgary, Calgary, Alberta, Canada. T2N 1N4. [#] muhammad.khan8@ucalgary.ca, [†] gachari@ucalgary.ca, [‡] jhatay@ucalgary.ca



SCHULICH School of Engineering

INTRODUCTION

Background:

- The **consumption** of pharmaceuticals has increased dramatically around the world in recent years. For example:
- 60.4 million prescriptions were handed out in US pharmacies in 2012.¹
- Sales of prescription drugs in Canada alone escalated to **US\$8 million** in a period of four years.²
- Recent studies have shown that traces of several pharmaceuticals have started to emerge in Municipal Wastewaters (MWW) and Groundwater (GW). Due to inefficient conventional treatments in practice at wastewater treatment plants (WWTPs), these emerging substances of concerns (ESOCs) are now being detected in receiving water bodies such as rivers, streams and aquifers that serve as drinking water sources.³
- Long term exposure to these contaminants could be **harmful** to aquatic life and potentially to humans.

Advancement in biological and chemical wastewater



Table 1. ESUCS Delected in Surface and Drinking Waters of Calgary

Pharmaceuticals	Groups	Pharmaceuticals	Groups	
Metformin	Anti-Diabetic	Sulfamethoxazole	Antibiotics	
Caffeine	CNS* Stimulant	Venlafaxine	Antidepressant	
Carbamazepine	Antiepileptic	Gemfibrozil	Antihyperlipidemic	
Cotinine	Antidepressant	Ibuprofen	Anti-inflammatories	
Fluoxetine	Antidepressant	Naproxen	Anti-inflammatories	
Trimethoprim	Antibiotics	Diclofenac	Anti-inflammatories	
Ethynylestradiol	Estrogens	Estrone	Estrogens	
*Contral Norvous System				

To develop and optimize an integrated technology for enhanced overall removal of ESOCs from MWW.



TECHNOLOGY APPLICATION

Case 1 and 2:

Bench scale studies will be completed in Laboratory. Determination of optimized conditions will be followed by implementation of these technologies on pilot scale at ACWA facility to remove ESOCs from MWW.

Case 3 and 4:

These case studies will be carried out on bench scale. Aerobic granulation technology has the potential to replace conventional biological treatment in practice today with less footprint and lower capital cost. Future pilot scale testing will take place at ACWA facility.

REFERENCES

- C. Hampp, V. Borders-Hemphill, D. G. Moeny and D. K. Wysowski, *Diabetes Care*, 2014, **37**, 1367–1374.
- 2. IMS Health Canada, Unlocking the value of health information, www.imhealthcanada.com.
- 3. M. S. Fram and K. Belitz, *Sci. Total Environ.*, 2011, **409**, 3409–3417.
- 4. M. Chen, K. Ohman, C. Metcalfe, M. G. Ikonomou, P. L. Amatya and J. Wilson, Water Qual. Res. J. Canada, 2006, **41**, 351–364.
- 5. B. D. Blair, J. P. Crago, C. J. Hedman and R. D. Klaper, *Chemosphere*, 2013, **93**, 2116–2123.
- 6. T. aus der Beek, F. A. Weber, A. Bergmann, S. Hickmann, I. Ebert, A. Hein and A. K????ster, Environ. Toxicol. Chem., 2016, **35**, 823–835.
- 7. P. M. Bradley, C. A. Journey, D. T. Button, D. M. Carlisle, J. M. Clark, B. J. Mahler, N. Nakagaki, S. L. Qi, I. R. Waite and P. C. VanMetre, Environ. Sci. Technol. Lett., 2016, 243–249.